For the development of an implantable, low-energy therapy for the cardioversion of atrial fibrillation (AF), Cardialen,Inc has been awarded a $3 million National Institutes of Health (NIH) phase 2b SBIR grant. After an expert panel of cardiologists, scientists, and engineers gave the Cardialen therapy an exceptional peer review as part of a highly competitive grant process, the granted.
Maintaining rhythm control in heart failure patients has shown to improve the quality of life significantly. It also reduced mortality and hospitalization. For patients receiving a CRT-D device, Cardialen’s multipulse therapy could provide another essential tool. Atrial fibrillation is an irregular and rapid heart rate that can cause patient discomfort and increased risk of stroke. Worldwide, approximately 34 million patients suffer from this condition. Around 26% of patients with implantable cardioverter defibrillator and 36% of CRT-D patients receiving an implantable cardiac defibrillator have or most likely will develop atrial fibrillation.
For those patients already receiving an implantable cardiac resynchronization therapy, Cardialen seeks to provide a treatment.
Cardialen, Inc, is a Minneapolis-based medical device company producing implantable, low-energy defibrillation and cardioversion therapy for treating rapid heart rhythms, including, ventricular tachycardia and ventricular fibrillation, besides treating atrial fibrillation.